By Josh Beckerman
TherapeuticsMD, which owns the rights to pharmaceutical royalties, will consider strategic alternatives such as an acquisition, merger or asset sales.
The company developed women’s healthcare products before changing its model to focus on collecting royalties from its licensees. It isn’t engaged in research and development or commercial operations.
On Jan. 3, the company said that it received about $153.1 million in a licensing and asset sale transaction with Mayne Pharma Group. TherapeuticsMD said in August that “as we phase out our historical business operations, we remain focused on reducing costs and conserving cash.”
TherapeuticsMD also reported a third-quarter net loss from continuing operations of 13 cents a share, compared with a net loss from continuing operations of $1.58 a share a year earlier. Gross royalties were $1.2 million in the quarter.
Write to Josh Beckerman at [email protected]
Read the full article here
